CBL-B TR-FRET Assay Kit

Catalog #
79575
$2,200 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Human Casitas B-lineage lymphoma proto-oncogene b (CBL-B) is an E3 ubiquitin-protein ligase that functions as a negative regulator of T-cell activation. It is a promising drug target in cancer immunotherapy. The CBL-B TR-FRET Assay Kit is designed to measure CBL-B auto-ubiquitination activity in a homogeneous 384 reaction format. It utilizes biotin-labeled Ubiquitin and a terbium-labeled antibody recognizing the GST-tagged CBL-B protein to complete the TR-FRET pairing. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications.

Need us to run inhibitor screens or profile your compounds against CBL-B? Check out our Ubiquitination Screening & Profiling Services.

CBL-B TR-FRET

Figure: Illustration of Assay Principle

Need us to run inhibitor screens or profile your compounds against CBL-B? Check out our Ubiquitination Screening Services.

Synonyms
UBE1, UBA1, ubcH5b, UBE2D2, E3 ubiquitin-protein ligase CBL-B, RING finger protein 56, CBL, CBLB, cbl TR-FRET
Product Info
Storage and Usage
Citations
Assay Kit Format
TR-FRET
Supplied As
The CBL-B TR-FRET Assay Kit is designed to measure CBL-B auto-ubiquitination activity in a homogeneous 384 reaction format.
Materials Required But Not Supplied

Fluorescent microplate reader capable of measuring Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET)
Adjustable micropipettor and sterile tips

Format
Catalog # Component Amount Storage
80301 UBE1 (E1)* 10 µg -80 °C Avoid freeze/
thaw cycles
80314 UBCH5b (E2)* 100 µg -80 °C
80415 Human CBL-B (E3), GST-tag* 10 µg -80 °C
  Biotin-Ubiquitin 400 µl -80 °C
  ATP (400 μM) 150 µl -80 °C
  U2 assay buffer** 2 x 10 ml -80 °C
  Tb-labeled donor 10 µl -20°C
  Dye-labeled acceptor 10 µl -20°C
79969 White 384-well microtiter plate 1 Room 
Temp.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*The concentrations of E1, E2, and E3 enzymes are lot-specific and will be indicated on the tubes containing the enzyme.

UniProt #
UBE1: P22314; UBCH5b: P62837; CBL-B: Q13191
Background
CBL-B, a RING finger E3-ubiquitin ligase, acts as an intracellular checkpoint and a regulator of cytotoxic lymphocytes and NK cells. CBL-B binds E2-ubiqutin as well as target proteins such as TAM receptor TYRO3, forcing further degradation of TYRO3. CBL-B modulates innate immune responses and plays a key role in host defense to pathogens and anti-tumor immunity. Targeting CBL-B represents a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, tumors, and allergic airway inflammation. CBL-B has emerged as a new target of interest in the field of immunotherapy due to its ability to suppress cancer immune-evasion. CBL-B initiates anti-cancer immune responses in NK cells in both cytotoxic and effector T cells, promoting T-cell and NK cell activation.
References

1. Jeon, M.S., et al., Immunity. 2004; 21(2): 167-177

2. Chiang, Y.J. et al., Nature. 2000; 403: 216-220